Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env.
This study investigates whether genetically modified orally administered Lactococcus lactis (L lactis) could be used as an HIV vaccine. L lactis is immunogenic and extremely safe when delivered orally. We created a recombinant L lactis vector expressing the envelope protein of HIV on its cell surface. Oral immunization with this vector induced high levels of HIV-specific serum IgG and fecal IgA antibodies. Cell-mediated immune responses also were generated in both the regional lymph nodes and the spleen. Dendritic cells are readily infected by L lactis and appear to play a potential role in mediating the development of these immune responses. The protective efficacy of this vaccine strategy was demonstrated by challenging mice intraperitoneally with an HIV Env-expressing vaccinia virus. Their viral loads were 350-fold lower than those of control mice. These findings support the further development of L lactis-based HIV vaccines.
Xin
Ke-Qin
KQ
Department of Bacteriology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
Hoshino
Yuka
Y
Toda
Yoshihiko
Y
Igimi
Shizunobu
S
Kojima
Yoshitsugu
Y
Jounai
Nao
N
Ohba
Kenji
K
Kushiro
Akira
A
Kiwaki
Mayumi
M
Hamajima
Kenji
K
Klinman
Dennis
D
Okuda
Kenji
K
D016915:AIDS Vaccines; D000284:Administration, Oral; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology / Q000382:microbiology; D005260:Female; D005822:Genetic Vectors / Q000627:therapeutic use; D019302:HIV Envelope Protein gp160 / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000032:analysis; D007167:Immunotherapy / Q000379:methods*; D013294:Lactococcus lactis / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014616:Vaccinia virus / Q000187:drug effects; D019562:Viral Load
D016915:AIDS Vaccines; D019302:HIV Envelope Protein gp160; D007074:Immunoglobulin G; D011994:Recombinant Proteins